Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: Impact on drug discovery and early development

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1495-1507

  Peters, Sheila Annie ^a   Schroeder, Patricia E ^b   Giri, Nagdeep ^b,c   Dolgos, Hugues ^a,d  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER INC   (United States)

^d MERCK SERONO S A   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZ 1; AZ 10; AZ 11; AZ 2; AZ 3; AZ 4; AZ 5; AZ 6; AZ 7; AZ 9; CARBAMAZEPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DILTIAZEM; GUAIAZULENE; ITRACONAZOLE; KETOCONAZOLE; METOPROLOL; MIDAZOLAM; RIFAMPICIN; SIMVASTATIN; UNCLASSIFIED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG-DRUG INTERACTION; DYNAMIC MODEL; ENZYME INHIBITION; FIRST PASS EFFECT; HUMAN; INTERMETHOD COMPARISON; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; SIMULATOR; STATIC MODEL; STEADY STATE;

AREA UNDER CURVE; DRUG DISCOVERY; DRUG INTERACTIONS; MODELS, THEORETICAL;

EID: 84863947716     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.044602     Document Type: Article

References (39)

1. Almond LM, Yang J, Jamei M, Tucker GT, and Rostami-Hodjegan A (2009) Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 10:420-432.
2. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
3. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
4. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, and Barter ZE (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:623-638.
6. Einolf HJ (2007) Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257-1294.
7. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
8. Galetin A, Hinton LK, Burt H, Obach RS, and Houston JB (2007) Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693.
9. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
10. Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, and Galetin A (2011) Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 71:72-87.
11. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, and Heykants J (1986) Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 30:206-210.
12. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
13. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
14. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, and Rostami-Hodjegan A (2009) The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
15. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000a) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419-426.
16. Kanamitsu S, Ito K, and Sugiyama Y (2000b) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336-343.
17. Kato M, Chiba K, Ito T, Koue T, and Sugiyama Y (2010) Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. Drug Metab Pharmacokinet 25:367-378.
18. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
19. McGinnity DF, Zhang G, Kenny JR, Hamilton GA, Otmani S, Stams KR, Haney S, Brassil P, Stresser DM, and Riley RJ (2009) Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 37:1259-1268.
20. Obach RS (2009) Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Develop 12:81-89.
21. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
22. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
23. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
24. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
25. Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, and Bouzom F (2010) Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239-258.
26. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, and de Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748.
27. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
28. Shardlow CE, Generaux GT, MacLauchlin CC, Pons N, Skordos KW, and Bloomer JC (2011) Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Dispos 39:2076-2084.
29. Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L, and Skiles GL (2008) Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos 36:2355-2370.
30. Sinha VK, Snoeys J, Osselaer NV, Peer AV, Mackie C, and Heald D (2012) From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos 33:111-121.
31. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, and Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77-85.
32. Tucker GT, Houston JB, and Huang SM (2001) EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences. Eur J Pharm Sci 13:417-428.
33. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
34. Wang YH (2010) Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 38:1094-1104.
35. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 29:443-452.
36. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2005) Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 26:334-340.
37. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
38. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, et al. (2008) Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 65:680-692.
39. Zhou D, Andersson TB, and Grimm SW (2011) In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 39:703-710.